{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-092017","form_type":"8-K","ticker":"GPCR","cik":"0001888886","company_name":"Structure Therapeutics Inc.","filed_at":"2026-08-06T20:13:48+00:00","discovered_at":"2026-08-06T20:15:12.563301+00:00","generated_at":"2026-08-06T20:18:24.972373+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Structure Therapeutics Q2 net loss $106.2M; Phase 3 ACCOMPLISH program dosed first patients","bullets":["Net loss of $106.2M in Q2 2026 vs $61.7M in Q2 2025; R&D expenses $100.1M (up from $54.7M).","Cash, equivalents and short-term investments $1.3B as of June 30, 2026, expected to fund operations through 2028.","First patients dosed in Phase 3 ACCOMPLISH-1 and -2 trials of aleniglipron for chronic weight management.","Appointed John Berrios (ex-Novo Nordisk) as Chief Commercial Officer.","Phase 1 SAD data for ACCG-2671 and initiation of MAD trial on track for Q3 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-092017","json":"https://secwatch.observer/filing/0001104659-26-092017.json","markdown":"https://secwatch.observer/filing/0001104659-26-092017.md","text":"https://secwatch.observer/filing/0001104659-26-092017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888886/000110465926092017/0001104659-26-092017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888886/000110465926092017/tm2622407d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:18:24.972373+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}